- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00854100
Safety and Efficacy of Cariprazine As Adjunctive Therapy In Major Depressive Disorder
February 12, 2019 updated by: Forest Laboratories
A Double-Blind, Placebo-Controlled Study of Cariprazine (RGH-188) As Adjunctive Therapy In Major Depressive Disorder
This is an outpatient study to evaluate the safety, and efficacy of RGH-188 as an add-on therapy to standard antidepressants in patients who did not respond to previous antidepressant therapy.
Study Overview
Status
Completed
Conditions
Study Type
Interventional
Enrollment (Actual)
231
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Arizona
-
Phoenix, Arizona, United States, 85050
- Forest Investigative Site 040
-
Scottsdale, Arizona, United States, 85254
- Forest Investigative Site 038
-
-
California
-
Arcadia, California, United States, 91007
- Forest Investigative Site
-
Encino, California, United States, 91316
- Forest Investigative Site
-
Garden Grove, California, United States, 92845
- Forest Investigative Site
-
Irvine, California, United States, 92618
- Forest Investigative Site
-
Los Alamitos, California, United States, 90720
- Forest Investigative Site 013
-
National City, California, United States, 91950
- Forest Investigative Site 041
-
Oceanside, California, United States, 92056
- Forest Investigative Site
-
-
Colorado
-
Denver, Colorado, United States, 80239
- Forest Investigative Site 025
-
-
Connecticut
-
Norwich, Connecticut, United States, 06360
- Forest Investigative Site
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20016
- Forest Investigative Site
-
-
Florida
-
Jacksonville, Florida, United States, 32216
- Forest Investigative Site 007
-
West Palm Beach, Florida, United States, 33407
- Forest Investigative Site 012
-
-
Georgia
-
Atlanta, Georgia, United States, 30306
- Forest Investigative Site 033
-
Roswell, Georgia, United States, 30076
- Forest Investigative Site
-
-
Kansas
-
Overland Park, Kansas, United States, 66211
- Forest Investigative Site
-
-
Massachusetts
-
Fall River, Massachusetts, United States, 02721
- Forest Investigative Site 042
-
Pittsfield, Massachusetts, United States, 01267
- Forest Investigative Site 034
-
-
Nebraska
-
Omaha, Nebraska, United States, 68131
- Forest Investigative Site
-
-
New Jersey
-
Cherry Hill, New Jersey, United States, 08002
- Forest Investigative Site
-
-
New York
-
Bronx, New York, United States, 10467
- Forest Investigative Site 001
-
Brooklyn, New York, United States, 11235
- Forest Investigative Site 043
-
Mount Kisco, New York, United States, 10549
- Forest Investigative Site 020
-
New York, New York, United States, 10003
- Forest Investigative Site 039
-
New York, New York, United States, 10021
- Forest Investigative Site 029
-
-
North Carolina
-
Raleigh, North Carolina, United States, 27607
- Forest Investigative Site 032
-
-
Ohio
-
Canton, Ohio, United States, 44718
- Forest Investigative Site
-
Dayton, Ohio, United States, 45417
- Forest Investigative Site
-
-
Oregon
-
Portland, Oregon, United States, 97210
- Forest Investigative Site 015
-
-
Pennsylvania
-
Media, Pennsylvania, United States, 19063
- Forest Investigative Site 006
-
Philadelphia, Pennsylvania, United States, 19107
- Forest Investigative Site
-
Philadelphia, Pennsylvania, United States, 19104
- Forest Investigative Site
-
-
Tennessee
-
Memphis, Tennessee, United States, 38119
- Forest Investigative Site 023
-
Memphis, Tennessee, United States, 38119
- Forest Investigative Site 031
-
Nashville, Tennessee, United States, 37212
- Forest Investigative Site
-
-
Texas
-
San Antonio, Texas, United States, 78229
- Forest Investigative Site
-
-
Vermont
-
Woodstock, Vermont, United States, 05091
- Forest Investigative Site
-
-
Virginia
-
Richmond, Virginia, United States, 23230
- Forest Investigative Site
-
-
Washington
-
Bellevue, Washington, United States, 98007
- Forest Investigative Site
-
Seattle, Washington, United States, 98104
- Forest Investigative Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Men and women, 18-65 years old
- Currently meet the DSM-IV-TR criteria for moderate to severe MDD without psychotic features.
- Previous failure to respond to adequate trials of one or two ADTs with less than 50% reduction in depressive symptoms during the present episode.
Exclusion Criteria:
- DSM-IV-TR based diagnosis of an axis I disorder, other than MDD, or any axis I disorder other than MDD that was the primary focus of treatment within 6 months before Visit 1
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
PLACEBO_COMPARATOR: Placebo
Drug: Antidepressant (citalopram, duloxetine, escitalopram, sertraline, or venlafaxine XR) + Placebo
|
Drug: Antidepressant (citalopram, duloxetine, escitalopram, sertraline, or venlafaxine XR) + Placebo Oral, once daily for 8 weeks following an 8 week Prospective Treatment (Baseline) Period.
|
EXPERIMENTAL: Cariprazine 0.1 - 0.3 mg
Drug: Antidepressant (citalopram, duloxetine, escitalopram, sertraline, or venlafaxine XR)+ cariprazine low dose
|
Drug: Antidepressant (citalopram, duloxetine, escitalopram, sertraline, or venlafaxine XR) + cariprazine (0.1-0.3 mg/d) Oral, once daily for 8 weeks following an 8 week Prospective Treatment (Baseline) Period.
|
EXPERIMENTAL: Cariprazine 1.0 - 2.0 mg
Drug: Antidepressant (citalopram, duloxetine, escitalopram, sertraline, or venlafaxine XR) + cariprazine high dose
|
Drug: Antidepressant (citalopram, duloxetine, escitalopram, sertraline, or venlafaxine XR) + cariprazine (1-2 mg/d) Oral, once daily for 8 weeks following an 8 week Prospective Treatment (Baseline) Period.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Montgomery-Asberg Depression Rating Scale (MADRS)
Time Frame: Baseline (Week 8) to Week 16
|
The patient is rated on a scale from 0-6 on 10 items.
Apparent sadness, reported sadness, lassitude, pessimistic thoughts, inner tension, suicidal thoughts, reduced sleep and appetite, concentration difficulties, inability to feel.
The overall MADRS score ranges from 0-60, with 0 meaning no symptoms and score of 60 meaning maximum severity.
The primary efficacy parameter was the change in MADRS score totals from the scores taken at Baseline (Week 8) and during at least one more time point up to and including Week 16.
|
Baseline (Week 8) to Week 16
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinical Global Impression - Improvement (CGI-I)
Time Frame: Week 16
|
The Clinical Global Impression-Improvement (CGI-I) scale is a clinician rated scale that, in this study, will be used to rate total improvement or worsening of mental illness starting at Visit 2 (Week 2) and taken at every visit through Visit 11 (Week 16).
The patient will be rated on a scale from 1 to 7, 1 indicating that the patient is very much improved and 7 indicating that the patient is very much worse.
The secondary efficacy parameter was the CGI-I total score at Week 16.
|
Week 16
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Study Director: Robert Hayes, PhD, Forest Laboratories
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
June 30, 2009
Primary Completion (ACTUAL)
December 6, 2010
Study Completion (ACTUAL)
December 6, 2010
Study Registration Dates
First Submitted
February 26, 2009
First Submitted That Met QC Criteria
February 26, 2009
First Posted (ESTIMATE)
March 2, 2009
Study Record Updates
Last Update Posted (ACTUAL)
March 5, 2019
Last Update Submitted That Met QC Criteria
February 12, 2019
Last Verified
February 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- RGH-MD-71
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Major Depressive Disorder
-
Shalvata Mental Health CenterUnknownMAjor Depressive DisorderIsrael
-
York UniversityCentre for Addiction and Mental HealthSuspendedDisorder, Major DepressiveCanada
-
Seasons Biotechnology (Taizhou) Co., Ltd.CompletedMajor Depressive Disorder (MDDIndia
-
Gangnam Severance HospitalCompletedMajor Depressive Disorder(MDD)Korea, Republic of
-
University College, LondonCompletedUnipolar Major Depressive DisorderUnited Kingdom
-
Fundació Institut de Recerca de l'Hospital de la...Fondo de Investigacion SanitariaUnknown
-
Seasons Biotechnology (Taizhou) Co., Ltd.CompletedMajor Depressive Disorder (MDD)India
-
Repurposed Therapeutics, Inc.Unknown
-
GlaxoSmithKlineCompletedMajor Depressive Disorder (MDD)United States
-
AccexibleRecruitingMajor Depressive Disorder (MDD)Spain
Clinical Trials on Antidepressant + placebo
-
University of PennsylvaniaNational Institute of Mental Health (NIMH)Completed
-
Philipps University Marburg Medical CenterCompleted
-
Queens College, The City University of New YorkNational Institute of Mental Health (NIMH); New York State Psychiatric InstituteWithdrawnDepression | Depression in Old AgeUnited States
-
University Hospital, CaenActive, not recruitingPregnancy Related | Neonatal Hypotonia | Antidepressant Drug Adverse ReactionFrance
-
ShireCompletedMajor Depressive DisorderUnited States, Chile, Australia, Argentina, United Kingdom
-
First Affiliated Hospital of Zhejiang UniversityRecruitingDepressive DisorderChina
-
Peking UniversityRecruiting
-
M.D. Anderson Cancer CenterHealios Oncology NutritionTerminatedAdvanced CancersUnited States
-
Cota Inc.Hackensack Meridian Health; MYnd Analytics; Horizon Blue Cross Blue Shield of...Unknown
-
Emory UniversityTerminatedObsessive Compulsive Disorder | Major Depressive Disorder | Post-Traumatic Stress Disorder | Anxiety DisorderUnited States